India's second largest drugmaker Dr Reddy's Laboratories surprised investors yesterday, by announced that it had incurred a loss in its fiscal 2010 year third quarter ending December 31, 2009, and the firm's chief executive, GV Prasad warned that the company expected to post a "low single digit" revenue growth in the fiscal year that ends in March, down from its previous forecast of 10% growth over the previous year.
Consolidated revenues for the reporting period came in at 17.3 billion rupees ($373 million) against 18.4 billion rupees in third-quarter FY2009, representing a decline of 6%. Excluding revenues from sumatriptan in the previous year, the 17% growth was largely driven by the key markets of India and Russia in Global Generics and PSAI. Consolidated revenues for nine months to end December were up 9% at 53.9 billion rupees.
EBITDA was 3.7 billion rupees in the three month period and for nine months it reached 11.8 billion rupees, representing year on year growth of 31%.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze